Showing 3631-3640 of 4164 results for "".
- Adverum Announces Shortened Timelines and Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMDhttps://modernod.com/news/adverum-announces-shortened-timelines-and-clear-development-path-for-advm-022-intravitreal-gene-therapy-in-wet-amd/2478955/Adverum Biotechnologies announced that it has gained alignment with the FDA on the clinical development path for ADVM-022, an investigational single, in-office intravitreal (IVT) injection gene therapy for the treatment of wet age-related macular degeneration (AMD
- Visus Therapeutics Announces $36 Million Series A Financing to Advance Development of Novel Presbyopia-Correcting Eye Drophttps://modernod.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/Visus Therapeutics announced the close of a $36 million Series A Preferred Stock financing to advance the clinical development program for the company’s lead asset, Brimochol, an investigational drug designed to be a
- Enteral Lipid Supplement Reduces Severe Retinopathy Risk in Preterm Infantshttps://modernod.com/news/enteral-lipid-supplement-reduces-severe-retinopathy-risk-in-preterm-infants/2478838/Extremely premature infants who receive enteral lipid supplementation starting within 3 days of birth have a lower risk of severe retinopathy of prematurity than without supplementation, a clinical trial suggests, according to a Reuters report
- Timing of Cataract Removal in Infancy May Affect Glaucoma Riskhttps://modernod.com/news/timing-of-cataract-removal-in-infancy-may-affect-glaucoma-risk/2478700/A decade after undergoing cataract removal in infancy a substantial and increasing proportion of patients develop glaucoma or become glaucoma suspects, according to a secondary analysis of a randomized clinical trial, Reuters reported.
- Envision Announces Dates, Calls for Submissions for 2021 Conferenceshttps://modernod.com/news/envision-announces-dates-calls-for-submissions-for-2021-conferences/2478668/Envision announced that it is now accepting submissions for clinical education and research presentations for its two 2021 conferences—events with the goal of closing practice gaps and disseminating the latest advancements in rehabilitation techniques, research and technology surrounding low visi
- TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucomahttps://modernod.com/news/tearclear-announces-successful-completion-of-pre-ind-meeting-with-the-fda-for-a-preservative-free-multi-dose-delivery-of-latanoprost-for-the-treatment-of-glaucoma/2478608/TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration
- Oculus Names New Medical Directorhttps://modernod.com/news/oculus-names-new-medical-director/2478589/Oculus has announced that William Tullo, OD, FAAO, joined the company as a Medical Director on November 2nd, 2020. In this newly developed role, Dr. Tullo will provide clinical guidance and educate medical eye profess
- Fluocinolone Implant Real-World Experience Matches DME Trialshttps://modernod.com/news/fluocinolone-implant-real-world-experience-matches-dme-trials/2478565/A fluocinolone acetonide implant (Iluvien) administered under real-world circumstances works just as well for diabetic macular edema (DME) as it did in clinical trials, a new study suggests, Medscape reports. Patients who had not be
- Leiters and EyeConnect International Announce Corporate Partnershiphttps://modernod.com/news/leiters-and-eyeconnect-international-announce-corporate-partnership/2478520/Leiters, a provider of ophthalmic compounded sterile preparations and pharmacy services, has entered into a partnership with EyeConnect International (ECI) in support of their newly created digital ophthalmic clinical networking platform. Terms of the deal were not disclosed. EyeCon
- AstraZeneca to Test Long-Acting Antibody Treatment AZD7442 in COVID-19 Trialshttps://modernod.com/news/astrazeneca-to-test-long-acting-antibody-treatment-azd7442-in-covid-19-trials/2478403/AstraZeneca announced that it will advance its experimental long-acting antibody (LAAB) combination AZD7442 into two phase 3 clinical trials that are due to begin “in the next weeks.”